Thrombotic thrombocytopenic purpura and defective apoptosis due to CASP8/10 mutations: the role of mycophenolate mofetil
- PMID: 31714957
- PMCID: PMC6855129
- DOI: 10.1182/bloodadvances.2019000575
Thrombotic thrombocytopenic purpura and defective apoptosis due to CASP8/10 mutations: the role of mycophenolate mofetil
Abstract
Immunological dysregulation may underlie unusual autoimmune diseases, which also deserve to be investigated from a genetic point of view.
Conflict of interest statement
Conflict-of-interest disclosure: I.M. has received honoraria for participating as a speaker at an educational meeting organized by Instrumentation Laboratory and for participating at a Sanofi advisory board meeting. F.P. is a member of the scientific advisory board of Bioverativ, Roche, Sanofi, and Takeda. The remaining authors declare no competing financial interests.
Figures

References
-
- Joly BS, Coppo P, Veyradier A. Thrombotic thrombocytopenic purpura. Blood. 2017;129(21):2836-2846. - PubMed
-
- Joly BS, Stepanian A, Leblanc T, et al. ; French Reference Center for Thrombotic Microangiopathies . Child-onset and adolescent-onset acquired thrombotic thrombocytopenic purpura with severe ADAMTS13 deficiency: a cohort study of the French national registry for thrombotic microangiopathy. Lancet Haematol. 2016;3(11):e537-e546. - PubMed
-
- Rock GA, Shumak KH, Buskard NA, et al. ; Canadian Apheresis Study Group . Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. N Engl J Med. 1991;325(6):393-397. - PubMed